Incb001158 (Not yet branded)
Other Medications
Description
INCB001158 is an arginase inhibitor that blocks the enzyme arginase, which depletes arginine in the tumor microenvironment. This compound is designed to restore arginine availability to immune cells, particularly T cells, which require arginine for optimal function and proliferation. In colorectal cancer, it is evaluated primarily in combination with immunotherapy agents and chemotherapy regimens to enhance anti-tumor immune responses.
Mechanism of Action
INCB001158 selectively inhibits arginase enzymes (arginase 1 and arginase 2) that convert arginine to ornithine and urea. By preventing arginine depletion in the tumor microenvironment, this inhibition helps restore T cell function and proliferation, as these immune cells are highly dependent on arginine availability for their metabolic processes and cytotoxic activity.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.